These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4282 related articles for article (PubMed ID: 15829967)

  • 1. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
    Farmer H; McCabe N; Lord CJ; Tutt AN; Johnson DA; Richardson TB; Santarosa M; Dillon KJ; Hickson I; Knights C; Martin NM; Jackson SP; Smith GC; Ashworth A
    Nature; 2005 Apr; 434(7035):917-21. PubMed ID: 15829967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
    Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
    Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
    Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
    Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
    Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
    Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA damaging revolution.
    Cetin B; Wabl CA; Gumusay O
    Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kub5-Hera
    Motea EA; Fattah FJ; Xiao L; Girard L; Rommel A; Morales JC; Patidar P; Zhou Y; Porter A; Xie Y; Minna JD; Boothman DA
    Clin Cancer Res; 2018 Dec; 24(24):6459-6470. PubMed ID: 30108102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating cancer by targeting a weakness.
    Brody LC
    N Engl J Med; 2005 Sep; 353(9):949-50. PubMed ID: 16135843
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
    Ashworth A
    J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication fork stability confers chemoresistance in BRCA-deficient cells.
    Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
    Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors: its role in treatment of cancer.
    Chen A
    Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK; Yap TA; de Bono JS
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.
    Helleday T; Bryant HE; Schultz N
    Cell Cycle; 2005 Sep; 4(9):1176-8. PubMed ID: 16123586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 215.